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ABSTRACT
Background Since approval of tocilizumab (TCZ) for
treatment of rheumatoid arthritis (RA) and juvenile
idiopathic arthritis ( JIA), interleukin 6 (IL-6) pathway
inhibition was evaluated in trials of TCZ and other agents
targeting the IL-6 receptor and ligand in various RA
populations and other inﬂammatory diseases. This
consensus document informs on interference with the
IL-6 pathway based on evidence and expert opinion.
Methods Preparation of this document involved
international experts in RA treatment and RA patients.
A systematic literature search was performed that
focused on TCZ and other IL6-pathway inhibitors in RA
and other diseases. Subsequently, incorporating available
published evidence and expert opinion, the steering
committee and a broader expert committee (both
including RA patients) formulated the current consensus
statement.
Results The consensus statement covers use of TCZ as
combination- or monotherapy in various RA populations
and includes clinical, functional and structural aspects. The
statement also addresses the second approved indication
in Europe JIA and non-approved indications. Also early
phase trials involving additional agents that target the IL-6
receptor or IL-6 were evaluated. Safety concerns, including
haematological, hepatic and metabolic issues as well as
infections, are addressed likewise.
Conclusions The consensus statement identiﬁes points
to consider when using TCZ, regarding indications,
contraindications, screening, dose, comedication,
response evaluation and safety. The document is aimed at
supporting clinicians and informing patients, administrators
and payers on opportunities and limitations of IL-6
pathway inhibition.
SCOPE AND PURPOSE
The treatment of rheumatoid arthritis (RA) has sig-
niﬁcantly advanced over the past decade with the
recent optimisation of the use of synthetic disease
modifying anti-rheumatic drugs (sDMARDs), such
as methotrexate (MTX),1 2 newly developed
sDMARDs, such as leﬂunomide,3 4 and with the
addition of biological DMARDs (bDMARDs) to
the RA therapeutic armamentarium. The ﬁrst
bDMARDs studied and subsequently approved
were inhibitors of tumour necrosis factor (TNFi),5 6
followed by abatacept, an inhibitor of T-cell costi-
mulation,7 rituximab, an agent leading to B-cell
depletion8 and tocilizumab (TCZ), an interleukin 6
(IL-6) receptor blocker. Although there is little
direct comparison data between the ﬁve currently
approved TNFi (adalimumab, certolizumab pegol,
etanercept, golimumab and inﬂiximab) or other
bDMARDs, reviews and meta-analyses of clinical
trial data suggest these compounds have similar
efﬁcacy.9–12 They differ in terms of molecular struc-
tures (chimeric, humanised or human monoclonal
antibodies, or recombinant receptor constructs),
route of application (intravenous or subcutaneous),
and adverse event proﬁles, with these differences
determined by the agents’ modes of action. In con-
trast to bDMARDs, the modes of action of
sDMARDs are generally not well-understood, their
adverse event proﬁles are mostly different and their
costs are substantially lower.
Given the variety of available therapies and in
light of the variability discussed above, recommen-
dations for the management of RA have been devel-
oped.13 14 However, these recommendations,
despite their sophisticated and quite comprehensive
nature, capture only parts of the complexity of the
application of individual drugs. Therefore, consen-
sus statements on the use of groups of agents or
individual classes of agents have been developed,
providing pertinent information for various stake-
holders.15 16 Developing recommendations for indi-
vidual classes of drugs may bear the value of
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providing more detailed information on a particular agent than
can usually be offered by more general presentations. This is
especially true for describing the safety aspects of certain thera-
peutics, but can also be true for deliberations with regard to
efﬁcacy.
In the present manuscript, inhibition of the effects of IL-6
was the focal point of a consensus activity. Interference with
IL-6 is currently possible by using TCZ, a humanised monoclo-
nal antibody directed against the IL-6 receptor (IL-6-R), but
other compounds, such as another antibody targeting the
IL-6R and several agents focusing on the cytokine IL-6 itself,
are currently in development.17–20
An international group of experts and patient representatives
experienced in clinical research, the use of biological agents and
the development of consensus statements and treatment recom-
mendations, convened in Vienna in March 2012 to develop a
consensus statement on the current use of IL-6 pathway inhib-
ition in rheumatology. This statement targets primarily those
health professionals who prescribe IL-6 inhibition related thera-
pies, health professionals who do not primarily prescribe the
agent but care for patients treated with TCZ, as well as patients
interested in information on IL-6R or IL-6 inhibition. In
addition, this document may also be informative to payers, hos-
pital managers, administrators and other stakeholders interested
in treating RA and other chronic inﬂammatory diseases.
The consensus statement will address the following areas:
▸ Background on IL-6 and mode of action of TCZ and other
compounds
▸ Indication, considerations and screening for initiating TCZ
in RA
– Treatment dose algorithm and co-medication
– Evaluation of response and management of response
– Predictive factors of response
– Contraindications and adverse events
– Long-term exposure—efﬁcacy and safety issues
▸ Patient perspectives
▸ Research agenda
To achieve these objectives, a systematic literature review
(SLR) of the published literature on the efﬁcacy and safety of
TCZ and steering other biologicals inhibiting the IL-6 pathway
in patients with RA was ﬁrst undertaken to identify relevant
data, which also included abstracts of recent international con-
ferences, such as the European League Against Rheumatism
(EULAR) and American College of Rheumatology (ACR) meet-
ings of 2011 and abstracts known to be submitted to EULAR
2012 to be used and referenced if accepted for presentation.
The results of this SLR21 were presented to and discussed by
the committee, providing the basis for the discussions of the
large task force and the conclusions that will be presented
herein. Levels of evidence will be indicated next to each recom-
mendation, in line with published guidelines (see also online
supplement).22
BACKGROUND
IL-6 is a small polypeptide of approximately 26 kD molecular
weight that is involved in the differentiation and growth of a
variety of cells.23 24 It has originally been described as B-cell
stimulating factor, hepatocyte stimulating factor and interferon
β2, before it was cloned23 24 and shown that all these activities
were attributable to a single molecule which did not convey
antiviral actions. IL-6 binds to a receptor (IL-6R), which con-
sists of the actual cytokine binding part, the IL-6Rα chain, and
a second moiety, gp130, which transduces the respective signals
into the cell. A number of recent reviews have covered its mode
of action and related aspects in detail, and the reader is referred
to these and similar publications.23–27 More detailed insights
are also summarised in the online supplementary ﬁles.
TCZ, a humanised anti-IL-6R antibody directed to the
IL-6Rα chain, is currently the only IL-6 pathway inhibitor
licensed for the treatment of RA, and the evidence available on
safety and efﬁcacy therefore rests almost exclusively on infor-
mation related to this agent. However, other IL-6 inhibiting
therapies are currently in development and phase 2 data
already partly available; this information is also included in our
analysis.
MODE OF ACTION
Inhibition of the effects of IL-6 has been primarily studied in a
number of phase II and III clinical trials of TCZ. The original
designation of the antibody was myeloma receptor antibody,
since IL-6 is a growth factor for myeloma cells. TCZ showed
initial clinical efﬁcacy in collagen-induced arthritis in
monkeys;28 in a rare lymphoproliferative disorder, Castleman’s
disease;29 30 and also in early phase evaluations in RA.29 31–34
Its effects on acute phase reactant (APR) levels and other fea-
tures of chronic inﬂammation are fully in line with inhibition
of the above-mentioned modes of action of IL-6. However, it is
currently unknown if cells to which an anti-IL-6R antibody
binds, are lysed, undergo apoptosis, are ingested by phagocytes
of the spleen or others, or simply circulate with their receptor
being blocked. It is also unknown if binding of such antibodies
to the receptors might lead to cap formation and subsequent
ingestion of the IL-6R. These questions need to be addressed as
part of the research agenda.
RECOMMENDATION FOR THE USE OF TCZ
Indication, considerations and screening for initiating
TCZ in RA
Indication
Adult RA
In line with the current licensed indication in Europe, TCZ may
be used in adult patients with active RA, normally with at least
moderate disease activity according to a validated composite
measure, who have had an inadequate response to, or intoler-
ance of at least one synthetic DMARD and/or TNF-inhibitor.35
Before concluding that a patient has not sufﬁciently
responded to a previous synthetic DMARD or a TNF-blocker,
attempts should be made to improve the ongoing regimen by
optimising the respective DMARD or TNF-blocker dose, if indi-
cated, considering pertinent recommendations.14
TCZ fulﬁlled the requirements for the above indications as a
consequence of the results of several clinical trials (level 1a,
grade A). In table 1A, the response rates according to the ACR
improvement criteria36 as observed in phase III clinical trials
are depicted, showing superiority to control arms in all studies.
A signiﬁcant decrease in the disease activity score using 28
joint counts (DAS28) and high proportions of EULAR moderate
and good response as well as DAS28 remission (DAS28<2.6)
rates have been observed. However, interpretation of the
LATTER data is impeded by the high weight of the APR com-
ponent in the DAS28 formula37 38 and the prominent effect of
IL-6 inhibition on the hepatic APR production, which can lead
to exaggerated improvement or response rates when this
measure is employed. Nevertheless, the pre-eminent require-
ment of improvement in both swollen and tender joints to
fulﬁl ACR improvement criteria36 and the published clinical
trial data showing a decrease in disease activity across all vari-
ables studied as well as functional improvement and structural
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effects (table 1B), provide evidence that TCZ is an effective bio-
logical disease modifying drug. Indeed, when focusing on the
clinical disease activity index (CDAI), a score that does not
comprise an APR in its formula, TCZ remains signiﬁcantly
effective.39 Its efﬁcacy appears to be of similar magnitude as
that of TNF-inhibitors, abatacept and rituximab.9
TCZ has shown superior efﬁcacy compared with control
groups in the treatment of RA manifestations in combination
with MTX and other sDMARDs; TCZ was assessed mostly in
combination with MTX, but in some studies up to 20% of the
patients received other sDMARDs like leﬂunomide, sulfasala-
zine and/or chloroquine/hydroxychloroquine without notice-
able differences in efﬁcacy.41 52 TCZ was also effective as
monotherapy. Studies of other biologicals employed as mono-
therapy mostly revealed similar efﬁcacy as MTX and had gener-
ally less efﬁcacy than combination therapy.10 12 14 By contrast,
TCZ monotherapy has been shown in Japanese and an inter-
national trial to convey signiﬁcantly better efﬁcacy compared
with MTX (in MTX naïve or MTX never failed patients) or
other DMARDs in clinical, functional and, in the SAMURAI
trial, also structural respects, although it should be borne in
mind that in the Japanese studies MTX was dosed at only
8 mg weekly (level 1b, grade A; table 1A).45 48 50 A recent trial
comparing TCZ monotherapy with adalimumab monotherapy
(ADACTA trial) revealed clinical superiority of TCZ.49 While
this ﬁnding is not surprising given the fact that adalimumab
monotherapy was not shown to be clinically superior to MTX
monotherapy in early RA53 (and TCZ monotherapy was not
compared with a combination of ADA+MTX), the data impli-
citly conﬁrm the previous ﬁndings on the efﬁcacy of TCZ
monotherapy compared with DMARDs studied hitherto.45 48 50
For monotherapy, the 8 mg/kg dose is the only one studied in
phase 3 trials.
Adding TCZ to MTX (combination therapy) compared with
switching from MTX to TCZ monotherapy (withdrawal of
MTX) failed to convey superior clinical and structural effects in
Table 1A ACR20, 50 and 70% response rates (% of patients fulfilling improvement criteria) and percentage of HAQ change from baseline or
fulfilment of HAQ-MCID (reduction of more than 0.22) in different clinical trials of TCZ
FU Study
% of patients
fulfilling
ACR20
% of patients
fulfilling
ACR50
% of patients
fulfilling
ACR70
HAQ-decrease from
baseline (%) Comment
TCZ combination therapy
16 weeks CHARISMA33 7 arms, escalating doses of
TCZ monotherapy (2 vs 4 vs 8 mg/kg)
versus each dose in combination with MTX
74/41 53/29 37/16 MTX-IR
Results for 8 mg/kg combination therapy
versus MTX
24 weeks OPTION40 PL/TCZ 4/TCZ 8 mg/kg 26/48/59 11/31/44 2/12/22 21/33/34 MTX-IR
TOWARD41 PL/TCZ 8 mg/kg 25/61 9/38 3/21 13/33* MTX/DMARD-IR†
RADIATE42 PL/TCZ 4/TCZ 8 mg/kg 10/30/50 4/17/29 1/5/12 0/18/23 Anti-TNF-IR
ROSE43 PL vs TCZ 8 mg/kg 11/30 DMARD-IR†
52 weeks LITHE44‡ PL/TCZ 4/TCZ 8 mg/kg 25/47/56* 10/29/36* 4/16/20* 26/35/39* MTX-IR
TCZ monotherapy
12 weeks Japanese34 PL/TCZ 4 vs 8 mg/kg 11/57/78 2/26/40 0/20/16 DMARD-IR
16 weeks CHARISMA 7 arms, escalating doses of
TCZ monotherapy (2 vs 4 vs 8 mg/kg)
versus each dose in combination with MTX
63/41 41/29 16/16 MTX-IR
Results for 8 mg/kg monotherapy vs MTX
24 weeks AMBITION45 MTX/TCZ 8 mg/kg 53/70 34/44 15/28 33/44
ACT-RAY46 47 TCZ 8 mg/kg/TCZ 8 mg/kg
+MTX
70/72 40/46 25/25 33/33*,§ MTX-IR, switch to vs adding TCZ; LDA
and DAS28-REM were more frequent on
combination than TCZ mono-therapy
SATORI48 MTX/TCZ 8 mg/kg 25/80 11/49 6/30 25/50* MTX-IR
ADACTA,49 TCZ 8 mg/kg/ adalimumab
40 mg
65/49 47/28 33/18 n.a. Adalimumab monotherapy
52 weeks SAMURAI50 DMARDs/TCZ 8 mg/kg 34/78 13/64 6/44 10/50* DMARD-IR
Other IL-6 or IL-6R inhibitors (phase II; week 12)
12 weeks Anti-IL-6R
Sarilumab20 51 PL/150 mg 46/72 n.a. n.a. n.a.
Anti-IL-6
BMS94542919 PL/active 36/82¶ 15/50 6/43 29/39
Sirukumab17 PL/active 30/63¶ 3/27 n.a. n.a.
Olokizumab18 n.a. n.a. n.a. n.a.
*Estimated values using baseline data and approximate values from respective curves, since exact data not provided in the publications.
†DMARDs aside from MTX: sulfasalazine, leflunomide, antimalarials and other.
‡1 year data.
§Differences between groups in ACT-RAY not significant; all other studies showed significant differences from control; where studied, 4 mg/kg dose was also significantly
different from control; details see individual publications.
¶Highest response rate among several arms.
ACR, American College of Rheumatology; DMARDs, disease modifying antirheumatic drugs; DAS-28, disease activity score using 28 joint counts; FU, weeks of follow-up; HAQ,
Health Assessment questionnaire disability index; IR, insufficient response; LDA, low disease activity; MCID, minimally clinically important difference; MTX, methotrexate; n.a.,
not available; PL, placebo; TCZ, tocilizumab; TNF, tumour necrosis factor; for trial acronyms see respective publications.
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patients with established RA and active disease despite MTX
treatment for most endpoints (ACT-RAY trial; table 1A).46
Thus, these data further imply that monotherapy is effective
and is not signiﬁcantly inferior to combination therapy.
However, many of the assessments showed better numerical
outcomes in the combination therapy; moreover, at 6 months
and 12 months, signiﬁcantly more patients achieved DAS28 low
disease activity or remission, respectively, and less patients had
progression of joint damage on combination therapy compared
with monotherapy.47 Thus, while TCZ monotherapy is superior
to MTX monotherapy, a number of patients may beneﬁt from
the combination more than from switching to monotherapy.
However, if combination with MTX or other DMARDs is con-
traindicated and monotherapy with a biological agent is man-
dated, TCZ should be considered. In light of all of the above
aspects, a 3-arm trial comparing MTX, TCZ and the combin-
ation in early RA is still awaited to clarify these questions.
Throughout all studies assessing a 4 mg/kg and an 8 mg/kg
dose in combination with MTX, both doses had signiﬁcantly
better efﬁcacy than control regarding clinical functional and struc-
tural outcomes,44 40 42 but there was a consistent (though statis-
tically not signiﬁcant) clinical superiority of the higher dose (table
1A), which was particularly prominent for more profound levels
of efﬁcacy (eg, ACR70) and in patients who have failed TNFi;
these data suggest that many patients receiving TCZ at 4 mg/kg
will have only a limited, inadequate response and a majority no
profound response (level 1c, grade A). Trials investigating an
increase to 8 mg/kg after a starting dose of 4 mg/kg, as currently
recommended in the US, have not been systematically performed,
although in the clinical trials evaluating the 4 mg/kg dose, rescue
therapy with 8 mg/kg had been implemented in patients who did
not achieve at least 20% improvement in tender and swollen joint
counts by week 16;44 40 42 moreover, in a post-hoc analysis
TNFi-insufﬁcient responders (IR) and MTX-IR patients not
achieving an adequate response to TCZ 4 mg/kg by week 16
showed improvement after escalation to 8 mg/kg.54 Importantly,
the rate of anaphylactic reactions appears to be several fold higher
at the 4 mg/kg than at the 8 mg dose of TCZ (see below).55
A lower dose than 4 mg/kg is not recommended because of its
insufﬁcient efﬁcacy and even higher risk of immunogenicity.33 In
general, based on the available data, the task force felt that start-
ing combination therapy with a dose of 8 mg/kg and possibly
decreasing the dose when necessitated by adverse events may be
more appropriate than starting at 4 mg/kg due to the better efﬁ-
cacy and lesser immunogenicity of the higher dose; clinical and
laboratory monitoring is necessary at either dose.
TCZ has also shown signiﬁcant effects on retarding progres-
sion of joint damage, both in combination as well as monother-
apy;50 46 44 structural efﬁcacy was observed at both 4 mg/kg
and 8 mg/kg, where studied (table 1B). Moreover, TCZ
inhibited x-ray progression in patients with low as well as per-
sistent high clinical disease activity, thus dissociating the tight
link between disease activity and joint damage, as also seen
with TNF-blockers.56 TCZ is effective across all populations
investigated, that is, established and early RA; MTX-naïve,45
DMARD-IR33 41 52 48 46 44 40 and TNFi-IR42 patients (level 1a
to 1b, grade A). No differences in efﬁcacy were seen between
patients positive or negative for rheumatoid factor.52 57
In line with its mode of action, TCZ leads to a rapid reduc-
tion in APR, including C-reactive protein (CRP) levels, which is
sustained at the 8 mg/kg dose; in contrast, with 4 mg/kg CRP
decreases are not maintained throughout the 4 week time
course and this saw tooth pattern suggests an inadequate sup-
pression of the pathway at this dose.41 44 40 42 Further, TCZ
leads to an increase in haemoglobin levels, especially in RA
patients with anaemia, presumably by inhibiting the produc-
tion of hepcidin, a molecule stimulated by IL-6 and involved in
the pathways to anaemia of chronic disease;58 it may be thus
useful in RA patients with otherwise refractory anaemia of
chronic disease. The adverse event proﬁle will be discussed in
detail in subsequent sections.
Considerations for initiating treatment
Before starting any treatment for RA in general and thus also
TCZ, an individual therapeutic goal should be determined as a
shared decision between the patient and the treating physician,
who should be experienced in the diagnosis and treatment of
RA as well as the use of biological therapies and their complica-
tions14 59 (level 5, grade D). Several studies have shown that
RA patients cared for by physicians experienced in the manage-
ment of their disease, thus primarily rheumatologists, have
better outcomes than those followed by less specialised physi-
cians.60 61 Patients to whom the rheumatologist suggests treat-
ment with TCZ should have at least moderate disease activity
by composite scores, such as the DAS28 (>3.2), the Simpliﬁed
or CDAI (SDAI>11; CDAI>10) or similar scores62 (level 5,
grade D). A raised CRP is also preferable.
In the phase III trials, TCZ was started in patients with an
inadequate response to sDMARDs41 44 40 or also TNFi.42 TCZ
was used in combination with sDMARDs, primarily MTX, or
as monotherapy.33 45 50 46 44 When TNFi preceded TCZ
therapy, requirements for time of discontinuation were differ-
ent among prior agents: for etanercept it was at least 2 weeks,
while for adalimumab and inﬂiximab at least 8 weeks.42 In an
open label phase IV study, TCZ therapy was used within
1 month of stopping TNFi without any increases in serious
infections or other safety signals.63 In clinical practice it is
likely that TCZ will be frequently applied earlier than after
such intervals; however there are no available data supporting
the safety of TCZ in such cases.64 Of note, TCZ has not yet
Table 1B Radiographic changes in TCZ clinical trials assessing joint damage
Study Placebo+MTX 4 mg/kg+MTX 8 mg/kg+MTX 8 mg/kg mono-therapy DMARDs Assessment
LITHE†44 1.13 0.34* 0.29* GTSS, mean change from baseline
SAMURAI†50 2.3 (1.5–3.2)** 6.1 (4.2–8.0) vdH-TSS, mean (95%CI) change from baseline
ACT-RAY†46 0.08 (1.88) 0.22*** (1.11) Change of GTSS at 6 months; mean (SD)
ACT-RAY†47 92.4% 85.5%**** No radiographic progression at 1 year
*p<0.0001; **p<0.001; ***p=0.26; ****p=0.007; using as a cutoff the smallest detectable change of the Genant modified Sharp score of 1.5 (a relatively high value as a
cutoff for non-progression; data on lower values, such as 0 or 0.25 are awaited).
†The LITHE and SAMURAI data, including p values, relate to 1 year study results; for ACT-RAY, data shown reflect 6-month analyses which showed no significant differences
between TCZ monotherapy and combination with MTX.
DMARDs, disease modifying antirheumatic drugs; GTSS, Genant-modified total Sharp score; MTX, methotrexate; TCZ, tocilizumab; vdH-TSS, van der Heijde modified total Sharp
score.
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been studied in patients who had been previously exposed to
rituximab or abatacept, although data from an observational
study of small cohorts suggest some risk of infections in its use
after rituximab. Thus, more information will have to be
obtained from further trials or soon become available from
registries. Data from registries of patients receiving TCZ are
currently limited,65 but the registries will provide additional
information on the use of co-medications or patients treated in
the presence of comorbidities that were excluded from clinical
trials, as patients in clinical practice are usually more heteroge-
neous in these respects compared with trial populations.
Screening before initiating TCZ
In general, patients should be well informed about the risks
and beneﬁts of TCZ therapy (level 5, grade D).
Initiation of TCZ should be preceded by obtaining a detailed
history regarding chronic or recent co-morbidity, such as car-
diovascular, liver and pulmonary diseases, recurrent infections,
allergies, gastrointestinal perforations or diverticulitis, preg-
nancy or plans to become pregnant, and a complete physical
examination to consider possible contraindications in all
patients, especially the elderly. Special attention should be paid
to vaccinations which should be performed in accordance with
respective recommendations ideally before the administration
of TCZ.66 During TCZ therapy vaccination with live vaccines
(which includes rubella and shingles vaccines) should be
avoided (level 5, grade D).
A history of diverticulitis (note, not diverticulosis) should
alert the patient and treating physician, to a heightened risk of
gastrointestinal perforations during TCZ therapy.
Gastrointestinel (GI) perforations have been reported (incidence
0.1–0.2%), especially in patients with such history35 55 67 (level
4, grade C), although most were on glucocorticoids or non-
steroidal antirheumatic drugs (NSAIDs). Indeed, recent data
indicate that RA patients, regardless of DMARD therapy, have a
generally increased rate of GI perforation including both the
upper and lower GI tract, and the risk factors for this complica-
tion are glucocorticoid therapy, NSAIDs, and diverticulitis
history among others.68 At this time, further information is
needed to understand whether TCZ or other IL-6 inhibitors
further increase the risk of this complication beyond that
observed in the general RA population. Until then, however,
when IL-6 blocking therapy is prescribed in such patients,
efforts to eliminate or mitigate known risk factors for perfor-
ation should be undertaken where possible, and vigilance for
this potential complication should be maintained.
In clinical trials of TCZ, patients with RA were screened for
hepatitis B and C and excluded if testing positive. Likewise,
patients were excluded if they had active liver disease, indicated
by screening and baseline concentrations of alanine or aspartate
aminotransferase of 1.5 times the upper limit of normal (ULN)
or more. Of note, hepatic transaminase increases occurred more
frequently when TCZ was used in combination with MTX as
compared to monotherapy. The safety of TCZ in patients with
active hepatitis B or C virus (HBV, HCV) infections is currently
unknown. Clearly, in the presence of acute viral hepatitis TCZ
therapy is contraindicated. Also, in patients with chronic hepa-
titis B with poor liver function, TCZ therapy is not recom-
mended. In Japan, several case reports have been published in
which two HBV patients, in the context of concomitant anti-
viral therapy, and one HCV patient were successfully treated
with TCZ,69–72 and in a postmarketing surveillance report no
hepatobiliary disorders due to reactivation of hepatitis B or C
have been seen73 (level 4, grade C). Thus, in patients with
chronic hepatitis B and moderate to good liver function, treat-
ment with antiviral agents should be performed before consid-
ering TCZ therapy. In HBV carriers or in patients with latent
HBV infection (ie, HBs antigen negative, HBc or HBs antibody
positive) who show positive HBV DNA in peripheral blood,
prophylaxis should be considered before starting TCZ. Thus,
until further safety data are collected, TCZ treatment in
patients with chronic viral hepatitis can currently not be
recommended without antiviral prophylaxis in case of hepatitis
B,71 especially since reactivation of viral hepatitis has been
reported for other biological agents, such as TNF-inhibitors,
abatacept and rituximab74–77 (level 5, grade D).
While preclinical studies have not clearly deﬁned the role of
IL-6 in the defence against Mycobacterium tuberculosis,78 the
occurrence of tuberculosis has been reported in clinical trials
and postmarketing surveillance studies of TCZ73 79 (level 4,
grade C) and, therefore, patients should be screened for latent
tuberculosis according to local recommendations in the same
manner as for other biologicals; in the pivotal clinical trials
patients had been screened for tuberculosis. Chemoprophylaxis
prior to TCZ initiation should be given in patients diagnosed
with latent tuberculosis infection (level 5, grade D). Patients
with active tuberculosis are contraindicated for treatment with
TCZ.
Glucocorticoid therapy should be recorded and minimised or
tapered as rapidly as possible, since there are indications that
the risk of serious infections including opportunistic infections
is higher in TCZ treated patients with concomitant gluco-
corticoid therapy than in those without73 (level 4, grade C).
Regarding safety during and after pregnancy, currently only
limited data exist;80 81 there is no apparent evidence that IL-6
plays a role in fertility or gestation or TCZ leads to malforma-
tions, though IgG antibody transmission across the placenta has
been demonstrated with other biological agents. Nevertheless,
women of childbearing potential should use effective contracep-
tion during and until 3 months after cessation of therapy.
Currently it cannot be suggested to continue TCZ therapy in
women who become pregnant because only insufﬁcient safety
data exist; on the other hand, therapeutic abortion relies on a
thorough discussion between the physician and the mother.
Also, breast-feeding should not be done during TCZ therapy
(level 5, grade D).
Administration of TCZ in combination therapy and monotherapy
TCZ is administered as a monthly intravenous infusion,
usually over 1 hour. The approved initial dose in Europe and
most other regions of the world is 8 mg/kg, while in the USA
it is 4 mg/kg. The maximum recommended dose is 800 mg for
people with ≥100 kg bodyweight.35 55 A subcutaneous formula
is currently under investigation. Other IL-6 blockers that are
currently in phase 2 or 3 studies (see table 1A) are also applied
by the subcutaneous route.
TCZ is approved for use in combination with MTX and as
monotherapy if MTX is not tolerated or inappropriate.
However, TCZ has also been used in combination with a
variety of other sDMARDs.52 82
While it is recommended to lower the dose of TCZ when
certain adverse effects occur (see below), it is not clear at present
how one should proceed once patients reach the treatment
target, such as clinical remission or sustained low disease activ-
ity: can the dose be reduced, the interval between infusions
expanded, or should full treatment be continued? In a Japanese
study, only 13% of the patients maintained low disease activity
over 1 year after cessation of TCZ without use of any
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DMARDs. If the patients normalised MMP-3 and had low IL-6
levels, the retention rate reached 38%.83 Further study will need
to assess the impact of disease duration and DMARDs use on
the duration of response after TCZ is discontinued. It is also
unknown whether there will be a difference in the duration of
sustained efﬁcacy between early and established RA.
Evaluation of response and management of non-response
Response assessment should be done using composite measures
of disease activity, such as DAS, DAS28, SDAI and CDAI.
However, it should be borne in mind that APR are included in
all of these except for the CDAI. Because the effect of IL-6
inhibition on CRP levels or ESR may be profound despite lack
of clinical improvement, the actual response may be obscured
(see above). Therefore measures that do not comprise an APR,
such as the CDAI, are preferred (level 5, grade D). For the
future, treatment goals based on modern imaging modalities
that assess inﬂammatory activity, such as sonography or MRI,
if shown to be associated with important outcomes, may be
particularly relevant for patients using TCZ.
In line with respective recommendations,13 14 59 disease
activity assessment should be done initially monthly to every
3 months, aiming at a signiﬁcant improvement within
3 months and attaining low disease activity (CDAI≤10,
SDAI≤11, DAS28<3.2) or remission (using ACR-EULAR remis-
sion criteria84) within 6 months (level 5, grade D). Clinical trial
data suggest that clinical efﬁcacy is already seen within a few
weeks41 45 40 and, therefore, support the validity of the above
recommendations for response expectations.
If a patient does not achieve low disease activity within
6 months at an adequate dose (or does not experience a signiﬁ-
cant improvement of disease activity within 3 months) another
treatment option should be considered (level 5, grade D).
However, in the USA, where a starting dose of 4 mg/kg is
licensed (and which may convey more immunogenicity and
lower response rates as discussed above), a dose escalation may
have to be considered much earlier if signiﬁcant improvement
is not attained. Speciﬁc data to guide such dose escalation are
not well elaborated yet, since in clinical trials a dose increase
from 4 to 8 mg was usually done only after 16 weeks and only
in patients failing to achieve 20% reduction in tender and
swollen joint counts, a quite minimalistic requirement given
the baseline disease activity and length of time. Thus, in the
case of dose escalation, judging response adequacy may be
more appropriate after 3 and 6 months at the generally
accepted therapeutic dose of 8 mg/kg.
Cost-effectiveness
Despite the relatively limited time since approval, some eco-
nomic analyses on the use of TCZ have been published and,
with all reservations regarding such analyses at a relatively
early stage of use, revealed cost-effectiveness.85 86 More data
will be needed for full appreciation of the health economic
aspects of TCZ use.
Contraindications, adverse effects and long-term exposure
TCZ has been studied in several international and Japanese
trials, and most of these trials had long-term extension phases.
The long-term safety in Japanese patients as well as in the
international studies has been reported,87 88 and also the SLR
informing the present recommendations has focused partly on
safety;21 the reader is referred to these publications as well as
the package insert.35 55 87–89 A brief summary of adverse events
as derived from the above-mentioned studies and the package
insert is also provided in the online supplementary ﬁles, and
some have been discussed above under “Screening before initiat-
ing TCZ”. The items primarily addressed in the online supple-
ment are hypersensitivity, infections including hepatitis,
malignancies, changes of blood counts, lipids, gastrointestinal
perforations, hepatic manifestations and cardiovascular risk.
Dose adaptation or discontinuation in case of adverse events
and monitoring recommendations
While it is evident that in patients with infections, especially
serious ones, TCZ therapy has to be interrupted or sometimes
discontinued and therapy has to be withdrawn in the event of
infusion reactions, there are also speciﬁc laboratory abnormal-
ities that may require dose reductions or discontinuation. Thus
if transaminase elevations in the range of 1–3×ULN persist,
the dose should be reduced to 4 mg/kg or interrupted until nor-
malisation; if transaminases increase to >3×ULN, therapy
should be interrupted and can be resumed at lower dose when
levels are <3×ULN, and resumed at 8 mg/kg after transamin-
ase normalisation. For persistent (ie, seen at least twice)
increases >3×ULN or for any elevation >5×ULN, TCZ should
be permanently discontinued (level 5, grade D).
With respect to leukocytopenia, TCZ should be discontinued
if neutrophil counts are <500/mm3; at counts of 500–1000/
mm3, TCZ should be interrupted and resumed at 4 mg/kg once
neutrophil counts increase to >1000/mm3 (level 5, grade D).
Liver enzymes and bilirubin, complete blood count with differ-
ential and lipid levels should be assessed every 4 to 8 weeks for the
ﬁrst 6 months and every 3 months thereafter (level 5, grade D).
Patient perspectives
TCZ not only improves clinical signs and symptoms and joint
damage, but also all pertinent patient reported outcomes, such
as pain, physical function and quality of life; moreover, fatigue,
an important symptom identiﬁed by patients with RA, is sig-
niﬁcantly improved with TCZ.90 Patients should be fully
informed by their rheumatologist about the beneﬁts and risks of
TCZ therapy. Treatment initiation as well as the treatment
target should be based on a shared decision between the patient
and physician and appropriately recorded (level 5, grade D).
Other indications and experiences
While the focus of the present statement is on adult RA, several
other indications should be mentioned. TCZ is also licensed in
Europe and Japan for systemic juvenile idiopathic arthritis
(sJIA).55 In Japan, TCZ is also approved for use in polyarticular
JIA and Castleman’s disease. These data are supported by
respective publications30 91 92 (level 1b to 2b, grade B). The spe-
ciﬁc indications and licensing may differ among other countries.
There are also a number of other diseases in which TCZ has
been employed with or without success. According to several
case reports, TCZ has been effective in patients with secondary
amyloidosis, polymyalgia rheumatica, adult onset Still’s
disease, polymyositis, systemic sclerosis, large vessel vasculitis
(such as giant cell arteritis), and it has also been used in Lupus
with indications of some mild improvement.92–101 However,
none of these conditions are licensed indications and more
information will have to be obtained from formal clinical trials.
In part, these ﬁndings are in line with data on IL-6 inhibition
in experimental models of these diseases.102 In patients with
Castleman’s disease who frequently experience an interstitial
pneumonitis, lung disease has improved upon TCZ
therapy.103 104 In contrast, TCZ has revealed negative results in
case series and clinical trial of axial spondyloarthritis/
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ankylosing spondylitis,105–107 and this was also the case for a
study on sarilumab, another IL-6R inhibitor.108 Likewise, case
reports in psoriatic arthritis showed no clinical effect of TCZ
despite reduction in CRP,109 although these were small studies
in refractory patients. Nevertheless, the potential efﬁcacy of
antibodies to IL-6 rather than the IL-6R is currently unknown,
and the potential efﬁcacy of IL-6R blockade in patients with
peripheral spondyloarthritis remains to be investigated.
Finally, TCZ has also been evaluated in a small pilot con-
trolled study of Crohn’s disease and showed limited efﬁcacy
(20% clinical remission without effects on endoscopic and
histological changes) at doses of 8 mg/kg every other week.110
Research Agenda
The committee felt that many questions remained open and
needed to be addressed in future research in both adult and
paediatric populations. Some of these questions are presented
herein; they focus on TCZ but would equally be pertinent for
other compounds targeting the IL-6R or IL-6 and might be
addressed in the course of planned clinical trials.
Dose of TCZ and concomitant therapies
▸ Can TCZ be withdrawn, its dose reduced or the interval of
its administration expanded successfully in patients who
have attained low disease activity or remission?
▸ In the USA: when is it ideal to increase the TCZ dose from
4 to 8 mg/kg and what are the indicators that should lead
to this dose increase?
▸ Is TCZ monotherapy similarly effective as combination
therapy with MTX in early and established RA?
▸ What is the effect of other IL-6i when used as
monotherapy?
Efﬁcacy and assessment aspects
▸ What is the most suitable remission or low disease activity
target for TCZ, taking into account the speciﬁc effect on
APR (CDAI and/or a newer imaging modality with assess-
ment of synovitis activity?)
▸ Is IL-6 pathway inhibition efﬁcacious in patients with active
disease but normal CRP levels?
▸ What are predictors of response to IL-6-blockers?
▸ What are the effects of IL-6 inhibition on systemic
osteoporosis?
▸ Is the use of IL-6 inhibitors economically sound?
▸ What is the comparative efﬁcacy and safety proﬁle of TCZ
compared to other biological agents?
Safety in relation to other targeted therapies
▸ What are the efﬁcacy and safety when IL-6 pathway inhibi-
tors are given to patients previously treated with rituximab
(with or without persistent B-cell depletion) or abatacept?
▸ How safe are TNFi, abatacept and rituximab after IL-6i
therapy and vice versa?
▸ How safe are IL-6 inhibitors when combined with other
sDMARDs besides MTX?
▸ Are IL-6 inhibitors safe when used with or immediately
after Jak inhibitors, once these are licensed?
▸ Is there a need for a washout period after other biologicals
have been employed or can IL-6 inhibition be applied when
the next dose of the other biological is scheduled? And vice
versa, is there a need for a washout period for TCZ before
another biological can be used?
General safety aspects
▸ Is there a risk in patients with solid malignancies in the pre-
vious 5 years upon IL6 inhibition?
▸ Can patients with past/recent lymphoma or myeloma be
safely treated with TCZ?
▸ How safe are IL-6 inhibitors in patients with diabetes?
▸ What is the net effect of IL-6-blockers on cardiovascular risk?
▸ What is the mechanism for the change in lipids seen with
IL-6-blocking treatment?
▸ What is the involvement of IL-6 in defence against
Mycobacterium tuberculosis? Is the risk of reactivation of
latent tuberculosis truly increased among patients who
receive TCZ or other IL-6 inhibitors?
▸ Is the response to vaccines impaired during IL-6-blocker
therapy as it is during rituximab treatment?
▸ Is the risk of herpes zoster (shingles) increased with IL-6
inhibition?
▸ What are the predictors of anaphylactic reactions?
▸ How safe is the use of IL-6i in patients with hepatitis B or
C, treated with or without antiviral agents?
▸ Does the use of isoniazid lead to signiﬁcant increases in liver
function tests in patients with IL-6 inhibitor mono- and com-
bination therapy?
▸ What is the risk of GI perforations in patients treated with
IL-6-blockers? Is there any speciﬁc GI perforation associated with
these compounds, in the upper or lower gastrointestinal tract? Is
it related or unrelated to concomitant use of other drugs?
▸ Is there a risk to exacerbate or trigger demyelinating disor-
ders during treatment with IL-6 inhibitors?
▸ Are some forms of autoimmunity triggered upon the use of
IL-6 inhibiting therapy?
▸ Is there a need to stop therapy with IL-6-blockers before
fathering a child?
▸ What is the molecular effect of TCZ on target cells?
Other indications and aspects
▸ Larger trials should be performed for diseases like vasculitis
(including giant cell vasculitis), polymyalgia rheumatica, poly-
and dermatomyositis, systemic sclerosis, systemic lupus erythe-
matosus, adult onset Still’s disease, amyloidosis, and others.
▸ How should treatment with TCZ be approached in obese
people?
▸ What is the efﬁcacy and safety of using IL-6 inhibitors to
treat extra-articular manifestations of RA, including intersti-
tial lung disease and vasculitis?
CONCLUSION
In this consensus statement we provide recommendations for the
use of IL-6 pathway inhibition in clinical practice. The data are pri-
marily based on evidence assembled from clinical trials on TCZ,
currently the only approved agent targeting this pathway, but also
data of early phase clinical trials on other compounds that target
both the IL-6 receptor and ligand have been considered. As far as
available, these data conﬁrm the efﬁcacy and safety proﬁle of IL-6
pathway blockade. Currently approved indications are adult
rheumatoid and juvenile inﬂammatory arthritis. While other indi-
cations may follow with more available data, axial spondyloarthri-
tis appears to be refractory to this therapy. The recommendations
have been developed to provide guidance for rheumatologists and
other physicians engaged in the treatment of inﬂammatory dis-
eases as well as information for patients, payors and other sta-
keolders. They are summarised in the ‘Points to Consider’ (box 1).
which provide only a synopsis of the discussions for purposes of
general information. The details presented in the previous sections
should be regarded as part and parcel of these points.
Additional data will be needed to fully understand the value of
this treatment approach. Pertinent research question addressing
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open issues on safety, efﬁcacy and optimised use have been formu-
lated. The expected advancements will allow for a more reﬁned
use of TCZ and other IL-6 inhibitors in the future. However, the
already available information and the development of many add-
itional biologicals targeting IL-6 or its receptor reveal the import-
ance of this treatment option to improve the outcome in patients
with RA, JIA and possibly other inﬂammatory diseases.
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Box 1 Points to consider for the treatment of adult rheumatoid arthritis (RA) with tocilizumab (TCZ)*
Indication (level 1a, Grade A)
▸ RA with inadequate response to (or intolerance of ) at least one synthetic disease modifying antirheumatic drug (sDMARDs) or
tumour necrosis factor (TNF) inhibitor
– Active RA (at least moderate disease activity according to a validated composite measure)
Contraindications (level 5, grade D)
▸ Allergy to TCZ
▸ Clinically relevant co-morbidities, particularly active infections
Pre-treatment screening (level 5, grade D)
▸ History and physical examination
– Consider possible contraindications
– Consider radiograph of the chest
– Assess history of infections, diverticulitis and malignancies
▸ Routine laboratory testing, including lipid levels
▸ Testing for hepatitis B and hepatitis C viral infections
▸ Screening for tuberculosis
▸ Assess necessity of vaccination
Treatment dose and co-medication (level 1a, grade A)
▸ 8 mg/kg every 4 weeks as intravenous infusion, usually over 1 h
– While the approved starting dose in the US is 4 mg/kg, this is not recommended by the task force.
– A reduction from 8 to 4 mg/kg may be needed upon occurrence of certain adverse events.
▸ TCZ can be used in combination with methotrexate (MTX) (alternatively in combination with other sDMARDs) or as monotherapy, if
MTX is inappropriate.
▸ Evaluation and deﬁnition of response (level 5, grade D)
▸ Apply validated composite indices to assess treatment response
– Assess disease activity frequently especially during the ﬁrst months after initiation of TCZ
– Aim for remission (American College of Rheumatology-European League Against Rheumatism remission deﬁnition) or low disease
activity state (LDA: disease activity score using 28 joint counts ≤ 3.2, simpliﬁed disease activity index ≤ 11, Clinical disease
activity index ≤ 10)
– A signiﬁcant improvement should be achieved after 12 weeks and the treatment target should usually be reached after 24 weeks;
insufﬁcient response should normally lead to switching to an alternative therapy.
▸ Aim for improvement in function and quality of life
▸ Progression of structural changes should be prevented
Adverse events
▸ Infusion reactions (~7%)
– Severe infusion (hypersensitivity) reactions may occur but are rare (0.3%); they are more frequent with the 4 mg/kg than the
8 mg/kg dose
▸ Serious infections occurred about twice as frequently with TCZ compared to placebo population
▸ Hepatic transaminase elevations
▸ Gastrointestinal perforations, primarily in patients with a history of diverticulitis
▸ Neutropenia and rarely thrombocytopenia
▸ Effects of uncertain relevance
– Lipid increases (should be treated according to local guidelines)
*These points are a short abbreviation of the items discussed and presented in detail in the body of the text or in the online supplement. They should not
be applied independently of the information provided there in more detail, but present only an overview of the general scope of the recommendations.
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